Dr Abderrahim Oukessou, MD.
About Dr Abderrahim Oukessou, MD.
Dr. Abderrahim Oukessou, MD, is the Vice President and Development Team Leader for Oncology at Bristol Myers Squibb, with over 15 years of experience in oncology and hematology.
Company
Dr. Abderrahim Oukessou currently works at Bristol Myers Squibb in Princeton, New Jersey, United States. Bristol Myers Squibb is a global biopharmaceutical company known for its innovative medicines in various therapeutic areas, including oncology and hematology. Oukessou has held various leadership roles at the company, particularly in the oncology and hematology sectors.
Title
Dr. Abderrahim Oukessou holds the position of Vice President, Development Team Leader, Oncology at Bristol Myers Squibb since August 2020. In this role, he leads the global drug development efforts for oncology, focusing on developing innovative cancer treatments and improving patient outcomes.
Professional Background
Dr. Abderrahim Oukessou has over 15 years of experience in oncology and hematology within Bristol Myers Squibb. His roles have included Executive Director, Clinical Team Leader in Oncology Clinical Development, and Program Leader for Immuno-Oncology in Global Clinical Research. Before becoming Vice President, he also served as Medical Director for various sectors, including Global Clinical Research and Worldwide Hematology & Immuno-Oncology.
Previous Roles and Experience
Dr. Oukessou’s extensive career at Bristol Myers Squibb includes roles such as Worldwide Medical Director for Hematology & Immuno-Oncology, European Medical Lead for Oncology/Hematology at Europe HQ, and Head of the Oncology/Hematology Unit in France. He also served as Senior Medical Advisor in Global Medical Affairs and as Medical Advisor for Global Development and Medical Affairs. Before joining Bristol Myers Squibb, he worked as a Clinical Hematologist at Assistance Publique des Hôpitaux de Paris.
Clinical and Research Focus
Dr. Abderrahim Oukessou specializes in oncology and has a significant focus on immuno-oncology. He has been deeply involved in the development of new cancer therapies and clinical trials, leveraging his extensive experience in the field to contribute to innovative cancer treatment solutions. His dedication to improving patient outcomes in oncology is evident in his various leadership roles.